Darya Chudova has served as Guardant Health's Chief Technology Officer since May 2023. She has been with Guardant Health since August 2015, most recently serving as Senior Vice President of Technology.
In her role at Guardant Health, she initially focused on leading technical development of the Guardant360 Liquid and CDx products, improving the precision, robustness and accessibility of Guardant's liquid biopsy tests, and most recently led the development of Guardant's Shield technology for blood-based colorectal cancer screening, which has been approved by the U.S. Food and Drug Administration.
Prior to Guardant, Dr. Chudova developed non-invasive prenatal testing at Illumina, Inc. from March 2013 to August 2015, and developed tools for clinical diagnostics and interpretation of genomic expression and sequencing data in the context of molecular cytology at Veracyte, Inc. from 2008 to 2013. She holds a Ph.D. in Computer Science from the University of California, Irvine.